The FDA has started a priority review of Chiesi 's velmanase alfa, an enzyme replacement therapy for lysosomal storage disease (LSD) alpha-mannosidosis, with a decision expected in the first half ...

Chiesi GRD has an initial focus in developing therapies for lysosomal storage disorders (LSDs), including Fabry disease, as well as other rare diseases in haematology and opthalmology indications.

Chiesi UK & Ireland has published new research revealing significant gaps in the understanding and practice of inhaler use among UK asthma patients. The study published in the BMJ Open Respiratory ...